ClinicalTrials.gg
RecruitingNCT03371641ALCOBRAINUpdated Feb 6, 2026

In Utero Alcoholic Exposure: PlGF, Biomarker of Fetal Brain Lesions

An interventional study of ASQ parental questionnaire and Development scales in Fetal Alcohol Syndrome, sponsored by University Hospital, Rouen. Recruiting at 1 site in France. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by University Hospital, Rouen · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Primary completion was expected by Mar 2026, 7 months ago, but the record still lists the study as recruiting.
  • Registered 10 months after the study started (first participant enrolled Jan 2017, registered Nov 2017).
  • Started Jan 2017; still recruiting 9 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Study summary

This study aims to validate that PLGF is a biomarker of cerebral lesions and therefore of secondary developmental disorders and disabilities that will be best diagnosed at 2 and 6 years of age.

02

Conditions studied

  • Fetal Alcohol Syndrome

Keywords

  • Fetal Alcohol Syndrome
  • Pregnancy
  • Biomarker
  • PlGF
  • Cognitive development
  • Behavior troubles
03

In context

Fetal Alcohol Spectrum Disorders

65 studies on the registry are indexed under Fetal Alcohol Spectrum Disorders; 13 are open to participants now.

This study's planned enrollment of 60 is below the median of 74 across 57 interventional studies indexed under Fetal Alcohol Spectrum Disorders.

Browse Fetal Alcohol Spectrum Disorders studies →

Lead sponsor

University Hospital, Rouen is the lead sponsor of 418 studies on the registry; 106 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Mother:

  • Pregnant woman (monofetal or twin pregnancy, whatever the parity)
  • Age> or = to 18 years
  • Person affiliated to a social security system
  • Person who read and understood the information form and signed the consent form

    • Alcohol exposure group Chronic consumption of at least 30 g of alcohol per week or acute consumption of "binge drinking" type during pregnancy (knowing that a unit of 10 g of pure alcohol corresponds to 25 cl of beer 4 ° 5, 10 cl of wine at 12 °, 3 cl of whiskey, 7 cl of Porto ...)
    • Control group No alcohol consumption during pregnancy
    • Child Informed parents and written consent signed by the father and mother for the child's participation in this research (unless one of the parents does not have parental authority)

Exclusion criteria

Exclusion Criteria:

  • Female under 18
  • Pregnant woman with clinical suspicion of pre-eclampsia and / or HELLP syndrome
  • Person deprived of liberty by an administrative or judicial decision or protected major subject (under tutorship or curatorship)
  • Patient participating in another interventional trial or who participated in another interventional trial during pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Other
    Alcoholic exposure group

    Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire

    Behavioral: ASQ parental questionnaire · Behavioral: Development scales · Behavioral: Scale of Conners · Behavioral: SCQ Questionnaire · Procedure: Blood sample (mother) · Procedure: Cord blood sample · Procedure: Placenta sample

  • Other
    Control

    Blood sample (mother) Cord blood sample Placenta sample ASQ parental questionnaire WPPSI - IV and NEPSY development scales Scale of Conners SCQ questionnaire

    Behavioral: ASQ parental questionnaire · Behavioral: Development scales · Behavioral: Scale of Conners · Behavioral: SCQ Questionnaire · Procedure: Blood sample (mother) · Procedure: Cord blood sample · Procedure: Placenta sample

Interventions

  • BehavioralASQ parental questionnaire

    ASQ parental questionnaire

  • BehavioralDevelopment scales

    WPPSI - IV and NEPSY development scales

  • BehavioralScale of Conners

    Scale of Conners

  • BehavioralSCQ Questionnaire

    SCQ questionnaire

  • ProcedureBlood sample (mother)

    Blood sample (mother) before delivery

  • ProcedureCord blood sample

    Cord blood sample after delivery

  • ProcedurePlacenta sample

    Placenta sample

06

What researchers measure

Primary outcomes

  1. PLGF concentrations in the umbilical cord

    Compare concentrations between 2 groups of mother / child pairs: in utero exposure to alcohol versus control.

    Time frame: Through inclusion completion and samples analyses, an average of 4 months after the end of inclusions

  2. PLGF concentrations in placenta

    Compare concentrations between 2 groups of mother / child pairs: in utero exposure to alcohol versus control.

    Time frame: Through inclusion completion and samples analyses, an average of 4 months after the end of inclusions

Secondary outcomes

  1. Assessment of the concentration of PLGF in maternal blood

    Blood sample

    Time frame: Through inclusion completion and samples analyses, an average of 4 months after the end of inclusions

  2. Studies of metabolomic profile on blood sample

    blood sample metabolomic profile

    Time frame: Through inclusion completion and samples analyses, an average of 4 months after the end of inclusions

  3. Studies of metabolomic profile on placenta

    placenta metabolomic profile

    Time frame: Through inclusion completion and samples analyses, an average of 4 months after the end of inclusions

  4. Neurological clinical evaluation

    Clinical exam

    Time frame: The day of birth

  5. Follow-up at 2 years in pediatric consultation for evaluation of neuro-development

    ASQ: Ages \& Stages Questionnaires. This questionnaire screens and assesses the developmental performance of children in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal-social skills. It is used to identify children that would benefit from in-depth evaluation for developmental delays.

    Time frame: 2 years

  6. Follow-up at 6 years in consultation for assessment of neurodevelopment with

    parental ASQ: Ages \& Stages Questionnaire screens and assesses the developmental performance of children in the areas of communication, gross motor skills, fine motor skills, problem solving, and personal-social skills. It is used to identify children that would benefit from in-depth evaluation for developmental delays.

    Time frame: 6 years

  7. Follow-up at 6 years in consultation for assessment of neuropsychological assessment: Wechsler Preschool and Primary Scale of Intelligence: WPPSI IV

    WPPSI - IV: The Wechsler Preschool and Primary Scale of Intelligence consist of 14 subtests. They are designated as one of three types: core, supplemental, or optional. The core subtests are required for the computation of the Verbal, Performance, and Full Scale IQ. The supplemental subtests provide additional information about cognitive abilities or can be used as replacement for inappropriate subtests. The optional subtests provide additional information about cognitive functioning but cannot be used as replacements for core subtests. Quotient and Composite scores have a mean of 100 and a standard deviation of 15. Subtest scaled scores have a mean of 10 and a standard deviation of 3.elow 70 is Extremely Low, 70-79 is Borderline, 80-89 is Low Average, 90-109 is Average, 110-119 is High Average, 120-129 is Superior, 130+ is Very Superior.

    Time frame: 6 years

  8. Follow-up at 6 years in consultation for assessment of neuropsychological assessment: Developmental NEuroPSYchological Assessment

    NEPSY -NEuroPSYchological Assessment. The six functional domains are made up of 32 subtests and four delayed tasks. These domains are theoretically, not statistically, derived. The subtests were designed to assess cognitive abilities related to disorders that are typically diagnosed in childhood and that are required for success in an academic environment. These tests supposedly help detect any underlying deficiencies that may impede a child's learning

    Time frame: 6 years

  9. Follow-up at 6 years in consultation for assessment of neuropsychological assessment: Conners' scale

    Conners scale is assessing for attention deficit hyperactivity disorder (ADHD)

    Time frame: 6 years

  10. Follow-up at 6 years in consultation for assessment of neuropsychological assessment: SCQ Social Communication Questionnaire

    SCQ: The Social Communication is a 40 item, parent report screening measure that taps the symptomatology associaed with autism Spectrum disorder (ASD). The items are administered in a yes/non response format.

    Time frame: 6 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2017 (actual). Primary completion is estimated for Mar 2026, 110 months after the start.

Of 28 interventional studies with no phase under Fetal Alcohol Spectrum Disorders, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 43. This study's planned 110 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 29, 2017
First posted
Dec 13, 2017
StartActual
Jan 27, 2017
Primary completionEst.
Mar 27, 2026
CompletionEst.
Mar 27, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03371641
Responsible party
Sponsor
First posted
Dec 13, 2017
Start date
Jan 27, 2017
Primary completion
Mar 27, 2026 (estimated)
Completion
Mar 27, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

POURCHER
Contact
cecile.pourcher@chu-rouen.fr
02 32 88 82 65
BLOT
Contact
julien.blot@chu-rouen.fr
02 32 88 82 65

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion